About Natera

About Natera

Natera is a rapidly-growing diagnostics company with proprietary bioinformatics and molecular technology for analyzing DNA. Natera’s complex technology has been proven clinically and commercially in the prenatal testing space and the Company is actively researching its applications in the liquid biopsy space for developing products with oncology applications.

Since 2009, Natera has launched seven molecular diagnostic tests, many of which are available through major health plans accounting for more than 140 million covered lives in the United States. The Company’s own robust laboratory processes thousands of genetic tests per month.

Natera’s goal is to transform the way people – both providers and patients – respond to and manage genetic diseases.

Learn More About Natera

Stock Information

NTRA (Common Stock)
ExchangeNASDAQ CM (US Dollar)
Price$9.83
Change (%) Stock is Up 0.19 (0.00%)
Volume184,719
Data as of 08/26/16 4:00 p.m. ET
Minimum 15 minute delay
Refresh quote
Stock chart for: NTRA.O.  Currently trading at $9.83 with a 52 week high of $16.79 and a 52 week low of $6.52.

Recent News

Natera Reports Second Quarter 2016 Financial Results - 08/04/16
SAN CARLOS, Calif., Aug. 4, 2016 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results for the second quarter ended June 30, 2016 and prov... More»
Natera and UCSF Initiate Collaboration to Study DNA Markers of Kidney Transplant Rejection - 08/01/16
SAN CARLOS, Calif., Aug. 1, 2016 /PRNewswire/ -- Natera, Inc., (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, announced a research collaboration with the University of California, San Francisco... More»
Statement from the American College of Medical Genetics and Genomics Supports the Use of Non-Invasive Prenatal Testing for All Pregnant Women - 07/29/16
Natera, Inc. Praises New Practice Guidelines that Advocate NIPT screening for All Women, Regardless of Maternal Age SAN CARLOS, Calif., July 29, 2016 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), (NTRA), a leader in non-invasive genet... More»
Natera Announces Second Quarter Earnings Conference Call - 07/28/16
SAN CARLOS, Calif., July 28, 2016 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will release results for its second quarter ended June 30, ... More»
Unilabs Selects Natera, Inc.'s Panorama® Non-Invasive Prenatal Test (NIPT), Further Expanding Natera's Global Constellation™ Technology Transfer Business - 07/18/16
SAN CARLOS, Calif., July 18, 2016 /PRNewswire/ -- Natera (NASDAQ: NTRA),a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, and Swiss-based Unilabs, one of Europe's leading providers of clinical laboratory testing ... More»

Upcoming Events

There are currently no events scheduled.

Recent Presentations

There are currently no items available.

The information provided in this area of the website is maintained by a third-party service. Natera is not responsible for the accuracy, currency or completeness of the information contained herein.
Data provided by Nasdaq. Minimum 15 minutes delayed.
Shareholder Tools